MBRX Moleculin Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1659617 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY79.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-55.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.37x
Accruals ratio76.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $15.89M | $17.73M | $19.49M | $18.97M | $14.42M |
| SG&A expense | $9.12M | $8.79M | $10.02M | $11.54M | $8.39M |
| Operating income | -$25.10M | -$26.64M | -$29.63M | -$30.64M | -$22.97M |
| Pretax income | -$33.56M | -$26.05M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.56M | -$26.05M | -$29.77M | -$29.02M | -$15.89M |
| EBITDA | -$25.01M | -$26.52M | -$29.50M | -$30.51M | -$22.80M |
| EPS (basic) | -28.42 | -189.14 | -15.07 | -15.22 | -0.59 |
| EPS (diluted) | — | — | — | — | -0.59 |
| Weighted avg. shares (diluted) | — | — | — | — | 26.88M |
| Banking | |||||
| Net interest income | — | — | — | $240,000 | $306,000 |
| Balance sheet | |||||
| Cash & equivalents | $8.88M | $4.28M | $23.55M | $43.15M | $70.90M |
| Current assets | $9.69M | $5.19M | $26.27M | $45.60M | $72.50M |
| PP&E, net | $78,000 | $159,000 | $272,000 | $275,000 | $338,000 |
| Total assets | $22.13M | $16.93M | $38.22M | $57.42M | $84.09M |
| Current liabilities | $6.85M | $5.36M | $6.82M | $4.82M | $3.62M |
| Total liabilities | $7.12M | $5.72M | $12.14M | $5.23M | $5.10M |
| Shareholders' equity | $15.01M | $11.21M | $30.93M | $52.19M | $78.99M |
| Shares outstanding | 159,961 | 135,155 | 2.23M | 1.91M | 28.58M |
| Cash flow statement | |||||
| Operating cash flow | -$22.73M | -$23.86M | -$23.59M | -$27.64M | -$18.95M |
| Capital expenditure | $0 | $13,000 | $124,000 | $67,000 | $19,000 |
| Free cash flow | -$22.73M | -$23.88M | -$23.71M | -$27.71M | -$18.97M |
| Investing cash flow | $0 | -$13,000 | -$124,000 | -$67,000 | -$19,000 |
| Financing cash flow | $27.28M | $4.63M | $4.14M | -$23,000 | $74.72M |
| Depreciation & amortization | $90,000 | $126,000 | $127,000 | $130,000 | $164,000 |
| Stock-based compensation | $1.66M | $1.73M | $1.98M | $2.27M | $2.37M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.